VNBTrust National Association increased its position in shares of Allergan PLC. (NYSE:AGN) by 9.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,546 shares of the company’s stock after buying an additional 130 shares during the period. VNBTrust National Association’s holdings in Allergan PLC. were worth $376,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in AGN. Verde Servicos Internacionais S.A. boosted its stake in shares of Allergan PLC. by 3.4% in the second quarter. Verde Servicos Internacionais S.A. now owns 105,430 shares of the company’s stock worth $25,628,000 after buying an additional 3,453 shares during the period. Park National Corp OH boosted its stake in shares of Allergan PLC. by 5.6% in the second quarter. Park National Corp OH now owns 34,799 shares of the company’s stock worth $8,459,000 after buying an additional 1,837 shares during the period. Cacti Asset Management LLC boosted its stake in shares of Allergan PLC. by 1.0% in the second quarter. Cacti Asset Management LLC now owns 198,948 shares of the company’s stock worth $48,547,000 after buying an additional 2,028 shares during the period. Cpcm LLC boosted its stake in shares of Allergan PLC. by 30.9% in the first quarter. Cpcm LLC now owns 1,443 shares of the company’s stock worth $345,000 after buying an additional 341 shares during the period. Finally, Piedmont Investment Advisors LLC boosted its stake in shares of Allergan PLC. by 0.7% in the first quarter. Piedmont Investment Advisors LLC now owns 71,044 shares of the company’s stock worth $16,974,000 after buying an additional 504 shares during the period. 84.77% of the stock is owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (AGN) traded up 0.29% on Friday, reaching $232.88. 1,820,899 shares of the company’s stock traded hands. The firm has a market capitalization of $77.85 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16. The company has a 50 day moving average price of $245.93 and a 200 day moving average price of $238.13. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.35 EPS. On average, equities research analysts predict that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

ILLEGAL ACTIVITY WARNING: “VNBTrust National Association Boosts Position in Allergan PLC. (NYSE:AGN)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/12/vnbtrust-national-association-boosts-position-in-allergan-plc-nyseagn.html.

A number of brokerages recently weighed in on AGN. UBS AG reissued an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a research report on Wednesday. Deutsche Bank AG reissued a “buy” rating and issued a $278.00 price target (up from $273.00) on shares of Allergan PLC. in a research report on Wednesday. BidaskClub cut shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price target (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday. Finally, Credit Suisse Group set a $288.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Saturday, August 5th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and an average target price of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.